LOUISVILLE, Ky., Aug. 26, 2026 (GLOBE NEWSWIRE) — Onco360®, the nation’s leading independent Specialty Pharmacy, is grateful to be selected as a pharmacy partner by Revolution Medicines for RASONQUE™ (daraxonrasib), which is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.1
Source: Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib)
